Kudrna's Stock Market Talk

On April 10, 2012, Titan Pharmaceuticals (TTNP) announced it has entered into a definiative agreement to issue 6.517 million shares of common stock to institutional investors at $0.85 per share. The registered direct offering will provide gross proceeds of approximately $5.5 million in cash to Titan. Titan plans to use the proceeds to fund the preparation of a NDA for Probuphine, expected in October 2012, along with working capital and general corporate purposes. (more…)

Due to time constraints this week, this is the best I could get done for everyone.  As most of you know, I am now a restaurant owner and spending significant amounts of time trying to fix it to break-even. Hopefully I can resume the normal article schedule soon.  Remember, I’m a trader first and an author second which keeps this site free.  (more…)

We’ve got a new research report out today reiterating our ‘Neutral‘ position on DARA BioSciences, Inc. (DARA). In the report we highlight many of the recent events at the company over the past five months. (more…)

On March 26, 2012, Dr. Hsiao D. Lieu, MD, FACC, Nile Therapeutics’ (NLTX) Vice President of Clinical Research, presented the results from the company’s phase 1 safety and pharmacokinetic / pharmacodynamic (PK/PD) clinical trial with cenderitide at the 61th annual Scientific Session of the American College of Cardiology (ACC) meeting held in Chicago, IL. The poster presentation (board #628) was titled, “Initial Experience with Subcutaneous Infusion of Cenderitide in Patients with Chronic Heart Failure.” (more…)

Due to time constraints this week, this is the best I could get done for everyone.  As most of you know, I am now a restaurant owner and spending significant amounts of time trying to fix it to break-even. Hopefully I can resume the normal article schedule soon.  Remember, I’m a trader first and an author second which keeps this site free.  (more…)

AMZN had been in a trading range between $175 and $195 area
since mid-January. It broke out of that trading range on 3/26 with
above average volume and continued to move up with increasing
volume until today (3/28). It pulled back with less volume today in
a down market day and closed at 201.16. (more…)

NKE has been in an uptrend since it bounced off the $78 to
$79 area in August 2011. It closed at $107.88 on 3/27. (more…)

On March 26, 2012, Neurocrine Bio (NBIX) announced results from the company’s phase 2a program with NBI-98854, a VMAT2 inhibitor for the treatment of tardive dyskinesia (TD). We believe the results were overall a positive for the company, despite what management referred to as “inconsistent and incorrect application of the efficacy assessment protocol” at one of the eight sites used during the trial. When this site was removed (post-hoc), analysis of the primary and secondary endpoints showed encouraging results, we believe strong enough to warrant movement into a larger-scale phase 2b study. (more…)

Due to time constraints this week, this is the best I could get done for everyone.  As most of you know, I am now a restaurant owner and spending significant amounts of time trying to fix it to break-even. Hopefully I can resume the normal article schedule soon.  Remember, I’m a trader first and an author second which keeps this site free.  (more…)

Earlier in the week, Aastrom filed an S3 registering 4.526 million shares of Class A warrants that relate back to the companies January 2010 financing. These warrants are exercisable by the holders at $2.52 per share. (more…)